Composite
38%
Novelty
Feasibility
Impact
Mechanistic
70%
Druggability
55%
Safety
40%
Confidence
35%

Mechanistic description

This hypothesis proposes that activated microglia use TREM2 signaling to coordinate both synaptic pruning and oligodendrocyte precursor cell (OPC) recruitment in a spatially and temporally coupled manner. When microglia identify synapses for pruning through TREM2-dependent recognition of ‘eat-me’ signals, they simultaneously release specific chemokines (CCL2, CXCL12) and growth factors (PDGF-AA, FGF2) that recruit OPCs to the same neural circuits. This creates a coordinated remodeling process where synaptic elimination is followed by targeted remyelination of the remaining, strengthened connections. The TREM2 activation state determines both the specificity of synaptic pruning and the magnitude of OPC recruitment signals, ensuring that structural connectivity restoration occurs precisely where functional connectivity has been refined. In neurodegenerative diseases, this coordinated process becomes dysregulated—either through TREM2 dysfunction leading to inappropriate pruning, or through impaired microglial-OPC communication resulting in failed remyelination. The hypothesis predicts that enhancing TREM2 function will restore both appropriate synaptic selection and subsequent myelin repair in the same neural circuits. This can be tested by measuring synaptic density, myelin thickness, and OPC differentiation in TREM2-deficient versus TREM2-enhanced conditions, with the prediction that optimal outcomes require coordinated rather than independent activation of these processes. Therapeutic interventions targeting this axis could simultaneously address synaptic loss and white matter degradation through a unified microglial-mediated mechanism.

Evidence for (5)

  • TREM2 loss-of-function variants increase AD risk 2-4 fold

  • TREM2 is required for microglial response to amyloid plaques

  • TREM2 agonist promotes microglial clustering around plaques and reduces neurite dystrophy

  • Hub regions show heightened connectivity burden correlating with pathology

  • Synaptic loss in AD correlates with dysregulated microglial surveillance

Evidence against (4)

  • AL002c (TREM2 agonist) failed to meet primary endpoint in INVOKE-2 Phase 2 trial (2024)

  • TREM2 deficiency reduces amyloid pathology in some contexts (reduced microglial clustering)

  • Microglial states in AD are heterogeneous - single pathway modulation insufficient

  • Mouse-to-human microglial translation limitations affect validity

Bayesian persona consensus

51% posterior support

2 signals · 1 for / 1 against · agreement 50%

scidex.consensus.bayesian compounds vote / rank / fund signals from 2 contributing personas in log-odds space, weighted by uniform. Prior 50%.